文献速递前列腺癌

早发性转移性和临床晚期前列腺癌是独特的临床和分子实体,以TMPRSS2-ERG融合增加为特征

Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-01-08

本研究分析了10189例前列腺癌患者的综合基因组图谱数据,其中439例(4.3%)年龄≤50岁。结果显示,≤50岁患者TMPRSS2-ERG融合显著多于≥60岁患者,而AR拷贝数改变及SPOP和ASXL1突变显著较少。早发性晚期前列腺癌是具有特征性基因组改变的独特临床亚组。

要点

  • 早发性(≤50岁)晚期前列腺癌中TMPRSS2-ERG融合频率显著高于老年患者。
  • 早发性患者中AR拷贝数改变及SPOP、ASXL1突变频率显著较低。
  • 早发性晚期前列腺癌应视为具有独特分子特征的临床亚组。

核心结论

  • 临床晚期和转移性早发性前列腺癌是一个独特的临床亚组,具有特征性基因组改变,包括TMPRSS2-ERG融合频率增加以及AR、SPOP和ASXL1改变较少。

研究设计与样本

  • 回顾性分析2013年2月至2020年3月间接受商业化综合基因组分析的10189例前列腺癌患者的二代测序数据(中位年龄66岁,范围34-90岁)。

主要发现

  • 439例(4.3%)患者年龄≤50岁,1928例(18.9%)为51-59岁,7822例(76.8%)≥60岁。
  • 转移活检部位以淋巴结、肝和骨最常见,占所有标本的60.2%。
  • 97.4%的患者携带致病性基因组改变,最常见 altered 基因包括TP53、TMPRSS2-ERG、PTEN、AR、MYC、MLL2、RAD21、BRCA2、APC、SPOP、PIK3CA、RB1、MLL3、CDK12、ATM和CTNNB1。
  • ≤50岁患者TMPRSS2-ERG融合显著多于≥60岁患者,而AR拷贝数改变及SPOP和ASXL1突变显著较少。

临床怎么用

  • 对于早发性晚期前列腺癌患者,应考虑其独特的分子特征,TMPRSS2-ERG融合可能作为潜在生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Men with early-onset prostate cancer are at increased risk for cancer-related mortality, yet the prevalence and spectrum of molecular alterations in this patient population is unknown. Here, we analyze comprehensive genomic profiling data to characterize the molecular drivers of early-onset prostate cancer in patients with clinically advanced and metastatic disease. METHODS: Next-generation sequencing was ordered as a part of routine clinical care for 10,189 patients with prostate cancer between 02/2013 and 03/2020 using commercially available comprehensive genomic profiling. RESULTS: Deidentified genomic data for 10,189 unique patients with prostate cancer were obtained (median age = 66 y, range = 34-90 y). 439 patients were ≤50 y (4.3%), 1928 patients were between ages of 51 and 59 y (18.9%), and 7822 patients were ≥60 y (76.8%). Of metastatic biopsy sites, lymph node, liver, and bone were the most common in all groups, accounting for 60.2% of all specimens. Overall, 97.4% of patients harbored pathologic genomic alterations. The most commonly altered genes were TP53, TMPRSS2-ERG, PTEN, AR, MYC, MLL2, RAD21, BRCA2, APC, SPOP, PIK3CA, RB1, MLL3, CDK12, ATM, and CTNNB1. Patients ≤50 y harbored significantly more TMPRSS2-ERG fusions than patients ≥60 y, while AR copy number alterations as well as SPOP and ASXL1 mutations were significantly less frequent. CONCLUSIONS: Clinically advanced and metastatic early-onset prostate cancer is a distinct clinical subgroup with characteristic genomic alterations including increased frequency of TMPRSS2-ERG fusions and fewer AR, SPOP, and ASXL1 alterations.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Chalmers ZR, Burns MC, Ebot EM, et al. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions. Prostate Cancer Prostatic Dis. 2021. PMID: 33420417. doi:10.1038/s41391-020-00314-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。